(Q36944026)

17 August 2017

1 reference

title

Emerging drugs for non-small-cell lung cancer (English)

1 reference

17 August 2017

1 reference

Enriqueta Felip

1

0 references

Rafael Rosell

series ordinal

3

object named as

Rafael Rosell

1 reference

PubMed ID

17874972

17 August 2017

Mariacarmela Santarpia

series ordinal

2

object named as

Mariacarmela Santarpia

1 reference

PubMed ID

17874972

17 August 2017

language of work or name

English

0 references

publication date

1 September 2007

1 reference

Expert Opinion on Emerging Drugs

17 August 2017

1 reference

17 August 2017

12

1 reference

17 August 2017

3

1 reference

17 August 2017

449-460

1 reference

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

17 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.449

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.449

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.449

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.449

Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.449

Comparing antibody and small-molecule therapies for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.449

Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.449

Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.449

Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.449

Sunitinib: from rational design to clinical efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.449

The potential of antiangiogenic therapy in non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.449

Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.449

The evolving role of cetuximab in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.449

Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.449

Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.449

Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.449

Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.449

Epidermal growth factor receptor (EGFR) antibody down-regulates mutant receptors and inhibits tumors expressing EGFR mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.449

Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.449

Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.449

Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.449

Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.449

Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.449

Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the hum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.449

EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.449

Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.449

Efficacy and safety of paclitaxel poliglumex as first-line chemotherapy in patients at high risk with advanced-stage non-small-cell lung cancer: results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.449

A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.449

Vinflunine -- an active chemotherapy for treatment of advanced non-small-cell lung cancer previously treated with a platinum-based regimen: results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.449

Regulation of protein kinase C and role in cancer biology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.449

The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.449

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.449

A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.449

Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.449

Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.449

Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.449

Clinical development of histone deacetylase inhibitors as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.449

Prospects: histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.449

Discovery and development of SAHA as an anticancer agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.449

Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.449

Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lun

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.3.449

10.1517/14728214.12.3.449

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference

PubMed ID

17874972